Patent landscape highlighting double-edged scaffold of a WNT5A-agonizing peptide, Foxy5
Vikas Yadav1, Rubina Islam2, Hardeep Singh Tuli3
1Interdisciplinary Cluster for Applied Genoproteomics (GIGA), B34 Sart-Tilman, University of Liege (ULiege), Liege, 4000, Belgium.
Abstract:
Aberrant expression of the WNT signaling pathway has been associated with cancer progression and recurrence. Research over the decades has led to development of WNT-targetable small molecules, but has faced challenges in translating to clinics. Unlike WNT/β-catenin inhibitors, WNT5A-mimicking peptide, Foxy5 has shown encouraging efficacy in impairing metastasis of cancers with low or absent WNT5A expression. Recent patent application US20210008149 advocates the implication of Foxy5 for treatment and prevention of cancer relapse. The inventors have demonstrated the anti-stemness activity of Foxy5 in mice xenograft model via suppressing the expression of colonic cancer stem cell markers. Foxy5 also exhibits non-toxic nature when administered alone or in synergy with standard chemotherapy thus strengthening its candidature in the field of cancer therapeutics.
Insights
The WNT signaling pathway peptide Foxy5 shows promise in preventing cancer metastasis and relapse by targeting cancer stem cells. It demonstrates anti-cancer efficacy with a non-toxic profile, alone or with chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Aberrant WNT signaling pathway expression is linked to cancer progression and recurrence.
- WNT-targetable small molecules face challenges in clinical translation.
- WNT5A-mimicking peptide Foxy5 shows efficacy in impairing metastasis in cancers with low WNT5A expression.
Purpose of the Study:
- To evaluate the efficacy of Foxy5 in preventing cancer relapse and metastasis.
- To investigate the anti-stemness activity of Foxy5.
- To assess the safety and synergistic potential of Foxy5 with standard chemotherapy.
Main Methods:
- Utilized a mice xenograft model to demonstrate Foxy5's anti-stemness activity.
- Assessed the suppression of colonic cancer stem cell markers.
- Evaluated Foxy5's toxicity and synergy with chemotherapy.
Main Results:
- Foxy5 demonstrated anti-stemness activity by suppressing cancer stem cell markers.
- Foxy5 showed efficacy in impairing metastasis in relevant cancer models.
- Foxy5 exhibited a non-toxic nature when administered alone or with chemotherapy.
Conclusions:
- Foxy5 holds potential for cancer treatment and prevention of relapse.
- Foxy5's anti-stemness and anti-metastatic properties make it a promising therapeutic candidate.
- Foxy5's non-toxic profile supports its use in combination cancer therapy.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Hedgehog Signaling Pathway


